Drug Profile


Alternative Names: Immune therapeutic vaccine-1; Inactivated pepsin fraction HIV vaccine; IPF-ITV Phases; IPF-ITV-1; Irreversible pepsin fraction HIV vaccine; ITV-1

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Immunotech Laboratories
  • Class AIDS vaccines; Antivirals; Peptide vaccines
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II Hepatitis C

Most Recent Events

  • 22 Jun 2017 Immunotech Laboratories anticipates to complete the validation documentation and registration process for the manufacture of ITV 1 and submit an application to the Bulgarian Drug Administration by the end of September 2017
  • 14 Jun 2017 Phase-III clinical trials in HIV infections in Bulgaria prior to June 2017 (Parenteral)
  • 14 Jun 2017 Safety and efficacy results from a phase III trial in HIV infections released by Immunotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top